I think there is another explanation which is that Amarex has perhaps sent the unblinded data to the appropriate FDA’s who have been waiting for it ( US, Canada, UK, EU, Philippines). They have not provided the unblinded data to Cytodyn in my opinion since any clear results, good or bad would flip the SEC switch that they have to go public with the information. .instead , I believe Dr Kelly and NP want the completed report from the data to see the big picture , not just spot checking mortality information but how did the drug perform against all endpoints. Then request the EUA. Since J and J is getting reviewed by the FDA on the 26th , could our review possibly be that same day ?